Voya Investment Management LLC Increases Position in Albany Molecular Research, Inc. (AMRI)

Voya Investment Management LLC boosted its position in shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) by 13.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,857 shares of the biotechnology company’s stock after buying an additional 1,606 shares during the period. Voya Investment Management LLC’s holdings in Albany Molecular Research were worth $301,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Arizona State Retirement System boosted its stake in Albany Molecular Research by 0.9% during the second quarter. Arizona State Retirement System now owns 11,686 shares of the biotechnology company’s stock valued at $254,000 after buying an additional 100 shares during the last quarter. Texas Permanent School Fund boosted its stake in Albany Molecular Research by 0.9% during the second quarter. Texas Permanent School Fund now owns 16,299 shares of the biotechnology company’s stock valued at $354,000 after buying an additional 151 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its stake in Albany Molecular Research by 5.8% during the second quarter. Municipal Employees Retirement System of Michigan now owns 5,260 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 290 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Albany Molecular Research by 0.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 101,876 shares of the biotechnology company’s stock valued at $2,211,000 after buying an additional 589 shares during the last quarter. Finally, Thrivent Financial For Lutherans boosted its stake in Albany Molecular Research by 5.4% during the first quarter. Thrivent Financial For Lutherans now owns 12,640 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 650 shares during the last quarter. 72.10% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Voya Investment Management LLC Increases Position in Albany Molecular Research, Inc. (AMRI)” was originally published by Stock Observer and is owned by of Stock Observer. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.thestockobserver.com/2017/11/15/voya-investment-management-llc-increases-position-in-albany-molecular-research-inc-amri.html.

Separately, BidaskClub lowered Albany Molecular Research from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Five investment analysts have rated the stock with a hold rating, The stock presently has an average rating of “Hold” and a consensus target price of $18.00.

Shares of Albany Molecular Research, Inc. (NASDAQ AMRI) opened at $21.74 on Wednesday. Albany Molecular Research, Inc. has a one year low of $13.01 and a one year high of $22.17. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.37 and a current ratio of 0.68.

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Want to see what other hedge funds are holding AMRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albany Molecular Research, Inc. (NASDAQ:AMRI).

Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply